Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 with Bendamustine and Rituximab in Relapsed CLL/SLL
NCT01369849Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Started Sep 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01369849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369849.